FATE

Fate Therapeutics, Inc.

1.22

USD

FATE Earnings Reports

Positive Surprise Ratio

FATE beat 23 of 41 last estimates.

56%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q1 26 (Revenue/ EPS)

$1.08M

-$0.28

Implied change from Q4 25 (Revenue/ EPS)

-20.93%

+3.70%

Implied change from Q1 25 (Revenue/ EPS)

-33.55%

-12.50%

Fate Therapeutics, Inc. earnings per share and revenue

On Feb 26, 2026, FATE reported earnings of -0.27 USD per share (EPS) for Q4 25, beating the estimate of -0.27 USD, resulting in a 1.85% surprise. Revenue reached 1.37 million, compared to an expected 1.34 million, with a 1.85% difference. The market reacted with a +5.41% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.28 USD, with revenue projected to reach 1.08 million USD, implying an increase of 3.70% EPS, and decrease of -20.93% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

FAQ

What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Fate Therapeutics, Inc. reported EPS of -$0.27, beating estimates by 1.85%, and revenue of $1.37M, 1.85% above expectations.

How did the market react to Fate Therapeutics, Inc.'s Q4 2025 earnings?

The stock price moved up 5.41%, changed from $1.48 before the earnings release to $1.56 the day after.

When is Fate Therapeutics, Inc. expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?

Based on 13 analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.28 and revenue of $1.08M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.